These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30458835)

  • 1. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
    Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
    J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.
    Morichika K; Karube K; Sakihama S; Watanabe R; Kawaki M; Nishi Y; Nakachi S; Okamoto S; Takahara T; Satou A; Shimada S; Shimada K; Tsuzuki T; Fukushima T; Morishima S; Masuzaki H
    Am J Surg Pathol; 2021 Jun; 45(6):832-840. PubMed ID: 33899787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
    Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
    Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.
    Gupta M; Maurer MJ; Wellik LE; Law ME; Han JJ; Ozsan N; Micallef IN; Dogan A; Witzig TE
    Blood; 2012 Nov; 120(22):4400-6. PubMed ID: 23018644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
    Slak TC; Miceska S; Gasljevic G; Boltezar L; Kloboves-Prevodnik V
    Radiol Oncol; 2024 Mar; 58(1):99-109. PubMed ID: 38378036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Teoh SH; Khoo JJ; Abdul Salam DSD; Peh SC; Cheah SC
    Malays J Pathol; 2019 Dec; 41(3):273-281. PubMed ID: 31901912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
    Georgiou K; Chen L; Berglund M; Ren W; de Miranda NF; Lisboa S; Fangazio M; Zhu S; Hou Y; Wu K; Fang W; Wang X; Meng B; Zhang L; Zeng Y; Bhagat G; Nordenskjöld M; Sundström C; Enblad G; Dalla-Favera R; Zhang H; Teixeira MR; Pasqualucci L; Peng R; Pan-Hammarström Q
    Blood; 2016 Jun; 127(24):3026-34. PubMed ID: 27030389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
    Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
    Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
    Smith SD; Till BG; Shadman MS; Lynch RC; Cowan AJ; Wu QV; Voutsinas J; Rasmussen HA; Blue K; Ujjani CS; Shustov A; Cassaday RD; Fromm JR; Gopal AK
    Br J Haematol; 2020 Jun; 189(6):1119-1126. PubMed ID: 32030732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].
    Zhang F; Luo DL; Chen Y; Yan JH; Luo LQ; Liu J; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2020 Oct; 49(10):999-1002. PubMed ID: 32992412
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.